1. Generics Bulletin
  2. >>ESG

Medicines For Europe’s Sieger: ‘We Have To Create An Ecosystem Where We Can Compete’

Generics Bulletin Hosts Exclusive Interview With Association VP And Polpharma CEO

 
• By Dean Rudge

Markus Sieger, vice-president of off-patent industry association Medicines for Europe and CEO of Polpharma, spoke to Generics Bulletin about critical issues affecting supply in Europe, including pricing, supply chains, and his enthusiasm for ESG.

“We have these issues which we face in Europe. And the solution, I think, is not just to get money to build a factory, you know, or grants to develop products,” vice president of off-patent industry association Medicines for Europe and CEO of Polpharma, Markus Sieger, tells Generics Bulletin during an exclusive interview.

“I think we have to create an ecosystem where we can compete in supplying those products at a fair price

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ESG

‘Creating An Environment Where Women Can Thrive’ – Accord’s Carter Discusses The BGMA Women’s Networking Group

 
• By Dave Wallace

Marking International Women’s Day, Generics Bulletin speaks to Accord’s UK country manager Clara Carter about her role as chair of the BGMA’s new Women’s Networking Group.

‘A True Seat At The Table’ – Irish Industry Leader Sets Out Aspirations For New Pricing Deal

 
• By Dave Wallace

With a fresh pricing deal on the horizon, Medicines for Ireland chair and Teva country head Paul Neill talks to Generics Bulletin about the need for the Irish off-patent industry to have “a true seat at the table” and secure an agreement with the country’s government that better reflects the specificities of the generics and biosimilars market.

Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector

 
• By Urtė Fultinavičiūtė

With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.

Biosimilars Forum Sees Lessons Being Learned From US Humira Experience

 
• By Dave Wallace

In an interview with Generics Bulletin, Julie Reed, executive director of the US Biosimilars Forum, says that the low uptake for Humira rivals in the US has “raised everyone’s attention to what is going on and what is wrong with the system.”

More from Generics Bulletin

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.